Skip to main content
    S

    Sera Prognostics Inc (SERA)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.94
    -0.07 (-3.48%)

    Market Cap: $79.94M

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Sera Prognostics Inc (SERA) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Sera Prognostics (SERA) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Sera Prognostics reported EPS of -$0.16, below the -$0.14 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(13/23)
    Avg Surprise
    -4.66%

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.19 - -$0.15
    6 analysts
    Revenue Consensus
    $79.81K
    RangeN/A
    6 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.14
    Range-$0.15 - -$0.13
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.15+3.4%
    60d ago-$0.13-5.0%
    30d ago-$0.13-5.0%
    7d ago-$0.13-5.0%
    Current-$0.14
    Revenue Consensus
    $300.00K
    Range$100.00K - $600.00K
    3 analysts

    Next Report

    SERA has an expected report date of Mar 16, 2027.

    SERA Earnings Call

    The latest SERA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, SERA beat 13, missed 8 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $42000, up 162.5% from $16000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16-$0.14-$0.18 - -$0.10-14.29%MissN/A42 up, 0 downNov 4, 2026$42000
    Jun 30, 2026-$0.18-$0.14-$0.19 - -$0.13-28.57%MissN/A30 up, 0 downAug 12, 2026$30000
    Mar 31, 2026-$0.17-$0.17-$0.18 - -$0.160.00%In lineN/A31 up, 0 downMay 6, 2026$14000
    Dec 31, 2025-$0.16-$0.19-$0.20 - -$0.17+13.70%BeatN/A31 up, 0 downMar 18, 2026$10000
    Sep 30, 2025-$0.16-$0.21-$0.21 - -$0.21+23.81%BeatN/A11 up, 0 downNov 13, 2025$16000
    Jun 30, 2025-$0.16-$0.24-$0.24 - -$0.24+33.33%BeatN/A10 up, 1 downAug 6, 2025$17000
    Mar 31, 2025-$0.20-$0.21-$0.21 - -$0.21+4.76%BeatN/A11 up, 0 downMay 7, 2025$38000
    Dec 31, 2024-$0.25-$0.23-$0.25 - -$0.23-8.70%MissN/A21 up, 0 downMar 19, 2025$24000
    Sep 30, 2024-$0.24-$0.22-$0.22 - -$0.22-9.09%MissN/A20 up, 0 downNov 6, 2024$29000
    Jun 30, 2024-$0.25-$0.26-$0.30 - -$0.23+3.85%BeatN/A20 up, 0 downAug 7, 2024$24000
    Mar 31, 2024-$0.25-$0.27-$0.31 - -$0.23+7.41%BeatN/A20 up, 0 downMay 8, 2024N/A
    Dec 31, 2023-$0.25-$0.26-$0.27 - -$0.25+3.85%BeatN/A20 up, 0 downMar 20, 2024$41000
    Sep 30, 2023-$0.23-$0.35-$0.36 - -$0.30+34.29%BeatN/A30 up, 0 downNov 8, 2023$42000
    Jun 30, 2023-$0.34-$0.36-$0.39 - -$0.34+5.56%BeatN/A31 up, 0 downAug 9, 2023$123000
    Mar 31, 2023-$0.34-$0.38-$0.41 - -$0.35+10.53%BeatN/A30 up, 0 downMay 10, 2023$100000
    Dec 31, 2022-$0.31-$0.37-$0.44 - -$0.29+16.22%BeatN/A40 up, 0 downMar 22, 2023$65000
    Sep 30, 2022-$0.35-$0.62-$1.10 - -$0.34+43.55%BeatN/A40 up, 0 downNov 9, 2022$87000
    Jun 30, 2022-$0.37-$0.41-$0.46 - -$0.37+9.76%BeatN/A40 up, 0 downAug 10, 2022$78000
    Mar 31, 2022-$0.40-$0.37-$0.41 - -$0.33-8.11%MissN/A40 up, 0 downMay 10, 2022$38000
    Dec 31, 2021-$0.41-$0.29-$0.40 - -$0.18-41.38%MissN/A40 up, 0 downMar 29, 2022$26000
    Sep 30, 2021-$0.39-$0.25-$0.29 - -$0.22-56.00%MissN/A3N/ANov 9, 2021$23000
    Jun 30, 2021-$3.17-$1.26N/A-151.59%MissN/AN/AN/AJul 16, 2021$20000
    Mar 31, 2021-$0.17-$0.17N/A0.00%In lineN/AN/AN/AJun 2, 2021$13000
    Dec 31, 2020-$1.71N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$6000
    Dec 31, 2019-$1.48N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.68, after -$0.99 the year before. It was -$1.48 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.68N/A
    Dec 31, 2024-$0.99N/A
    Dec 31, 2023-$1.16N/A
    Dec 31, 2022-$1.43N/A
    Dec 31, 2021-$4.14N/A
    Dec 31, 2020-$1.71N/A
    Dec 31, 2019-$1.48N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,7788
    2026Q2Jun 30, 20264,8268
    2026Q1Mar 31, 20263,5696
    2025Q4Dec 31, 20254,3508
    2025Q3Sep 30, 20253,3566
    2025Q2Jun 30, 20253,4146
    2025Q1Mar 31, 20254,2296
    2024Q4Dec 31, 20244,9346

    2026Q3 Earnings Call

    Opening remarks

    Jennifer Zibuda Head of Investor Relations Thank you, operator. Welcome to Sera Prognostics Third Quarter 2026 Earnings Conference Call. Earlier today, Sera reported financial results for the quarter, which ended September 30, 2026. Joining me on today's call are Zhenya Lindgardt, President and Chief Executive Officer; Lee Anderson, Chief Commercial Officer; Tiffany Inglis, Chief Medical Officer; and Scott Gleason, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. A copy of today's earnings release can be found on the Investors section of our website at sera.com, and a replay of this webcast will also be available. We have also posted an accompanying slide deck presentation pertaining to today's earnings call on the Events section of our Investor Relations website. Before we begin, please note that today's discussion will include projections or forward-looking statements about events and circumstances that have not yet occurred, including regarding our business, future financial results and performance, and market opportunities. These statements are based on our current expectations and are subject to risk factors and uncertainties that could cause actual results to differ materially and adversely from these expectations and forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q, and 8-K, for important information regarding these risk factors. With that, I will turn the call over to Zhenya.

    Evguenia Lindgardt President and Chief Executive Officer Good afternoon, everyone, and thank you for joining us today. At Sera, we believe we're building something truly unique in health care. We have developed one of the most highly validated advanced lab tests in history, addressing one of the most important and underserved challenges in medicine: preterm birth. The PreTRM test has demonstrated the ability to identify high-risk pregnancies early and drive meaningful improvements in outcomes for mothers and babies. We're no longer simply an evidence-generation story. We're actively transitioning into the commercialization phase of our journey, with the goal of establishing PreTRM as a foundational component of prenatal care. The opportunity remains largely untapped, with no effective standard for broad population screening of preterm birth risk. As a result, we believe there is the potential to create a new category in prenatal care and address one of the largest unmet needs in health care while driving substantial long-term value for shareholders. The third quarter represented a significant step forward in that journey. Following publication of the landmark PRIME study and the addition of highly experienced commercial leaders to our management team, we saw strong momentum in the third quarter. Compared to the first quarter of this year, the number of physicians ordering PreTRM nearly tripled, while test volume increased approximately fivefold.

    Frequently Asked Questions About SERA

    When is Sera Prognostics's next earnings date?

    Sera Prognostics's next earnings report is expected for Mar 16, 2027.

    Did SERA beat earnings estimates last quarter?

    No. Sera Prognostics reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 14.29%.

    What EPS do analysts expect from SERA next quarter?

    The consensus EPS estimate for Sera Prognostics for the quarter ending Dec 31, 2026 is -$0.16 from 6 analysts, with estimates from -$0.19 to -$0.15.

    How often does SERA beat earnings estimates?

    Sera Prognostics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.01%.